Key clinical point: A less rigid immunization schedule may be a safe and effective way to facilitate coadministration of human papillomavirus vaccine with other vaccines and thereby reduce vaccination visits.
Major finding: Giving the second dose of an human papillomavirus vaccine either 6 months or up to 8 years after the first didn’t affect the magnitude of the immune response.
Study details: This was a post hoc comparison of the immune responses elicited by two doses of human papillomavirus vaccines given either 6 months or a mean of 5.4 years apart in two clinical trials.
Disclosures: The presenter reported having no financial conflicts regarding the study, conducted free of commercial support.
Gilca V et al. ESPID 2019, Abstract.